Botswana has 2.5 million people and a health system that has changed more than most in the past two decades. The Botswana healthcare system went from catastrophic HIV/AIDS mortality in the late 1990s to meeting the UNAIDS 95-95-95 treatment targets by 2024. Classified as upper-middle-income by the World Bank, with a GDP of approximately USD 19.4 billion (2024), Botswana spends a larger share of national resources on health than most of its regional peers. For pharmaceutical companies, CROs, and global health organisations evaluating Southern African markets, Botswana has strong government commitment, established research partnerships, and a population-level dataset shaped by two decades of national treatment programmes.
Botswana's Healthcare System at a Glance
Botswana's health indicators are consistent with its income status and sustained government spending. Life expectancy at birth reached 70 years in 2024, a dramatic recovery from roughly 46 to 47 years around 2000-2001, when HIV/AIDS mortality was at its peak (UNDP demographic analysis of the 2001 census; WHO country data). The country's under-five mortality rate has declined steadily, and access to primary care is among the highest on the continent.
Key statistics:
- Population: approximately 2.5 million (2024)
- Life expectancy at birth: 70 years (2024, Macrotrends)
- HIV prevalence: 20.8 percent among adults aged 15 to 64 (BAIS V, 2021)
- Health expenditure as share of GDP: approximately 6.2 percent (World Bank, 2020 data)
- Government share of total health expenditure: approximately 57 percent
- Public health facilities: 35 hospitals, 105 clinics with beds, 206 clinics without beds, 351 health posts, and 931 mobile stops
The government provides universal healthcare to all citizens through the public system, and the state operates roughly 98 percent of all medical facilities. Vision 2036 frames health under its Human and Social Development pillar, targeting high-income status with a healthy, productive population. In May 2025, Botswana launched a National Health Insurance scheme to formalise UHC and bring structure to the financing side. Private healthcare exists but plays a smaller role than in neighbouring South Africa, where the private sector absorbs nearly half of total health spending.
Health System Structure and Financing
Healthcare in Botswana is organised through a three-tier public hospital system, overseen by the Ministry of Health and Wellness and delivered across 27 health districts.
- Primary hospitals: 17 facilities located in rural areas, each serving up to 10,000 people with between 20 and 70 beds
- District hospitals: 15 facilities in larger towns and cities, with between 71 and 250 beds
- Referral hospitals: 3 specialised hospitals handling cases that exceed district capacity
Princess Marina Hospital in Gaborone is the largest referral hospital in the country, with approximately 530 inpatient beds. It also serves as the primary teaching hospital for the University of Botswana's Faculty of Medicine. The hospital regularly operates above capacity, with average admissions reaching 650 patients against its 567-bed design.
The government allocates approximately 11 percent of total public expenditure to health, according to UNICEF estimates. This is supplemented by international funding, particularly from PEPFAR, which provided over USD 90 million annually at its peak in 2009 before declining to around USD 40 million by 2014. Recent cuts to US global health funding have created further pressure on externally supported programmes.
A persistent workforce challenge shapes service delivery. Botswana has historically relied on importing doctors, both generalists and specialists. The University of Botswana's medical school is relatively new, and the country continues to face shortages in rural areas despite strong urban facility coverage.
The HIV/AIDS Response: A Global Model
Botswana's HIV response is the central fact of its health system, and the reason it has the clinical data infrastructure it does. In January 2002, Botswana became the first country in sub-Saharan Africa to offer free antiretroviral therapy (ART) to all eligible citizens through its national Masa programme (meaning "new dawn" in Setswana).
The outcomes speak for themselves. According to the Fifth Botswana AIDS Impact Survey (BAIS V, 2021), published in The Lancet HIV in 2024:
- 95.1 percent of people living with HIV aged 15 to 64 knew their status
- 98.0 percent of those aware of their status were on ART
- 97.9 percent of those on ART had achieved viral load suppression
These figures mean Botswana has met all three UNAIDS 95-95-95 targets, placing it among a small group of countries worldwide to do so by the end of 2024. The prevalence of viral load suppression among all people living with HIV was 91.8 percent nationally.
In May 2025, Botswana became the first high-HIV-burden country, and the first in Africa, to achieve WHO gold tier status for eliminating mother-to-child transmission of HIV. The rate of vertical transmission dropped to 1.2 percent, well below the 5 percent benchmark, with fewer than 100 infants born with HIV in 2023. This achievement built on Botswana's earlier silver tier certification in 2021.
The Botswana HIV programme has generated one of the longest continuous treatment datasets in Africa, with Masa programme data spanning from 2002 to the present. That dataset has real value for longitudinal research, treatment outcome analysis, and epidemiological modelling. Platforms like Kapsule, which structure and de-identify clinical records for research use, can help unlock the analytical potential of such long-running national treatment programmes.
Disease Burden Beyond HIV
HIV dominates the health narrative, but Botswana also faces a growing non-communicable disease (NCD) burden alongside its infectious disease load.
NCDs accounted for 46 percent of all deaths in Botswana, according to 2016 WHO estimates. The WHO STEPS survey (2014) documented the following prevalence rates among adults:
- Hypertension: 29 percent
- Obesity: 30 percent
- Tobacco use: 18 percent
- Diabetes: 5 percent
- Unhealthy diet: 95 percent
Cardiovascular diseases accounted for 18 percent of NCD deaths, cancer for 7 percent, diabetes for 6 percent, and chronic respiratory diseases for 4 percent. These figures are likely to have worsened since the 2014 STEPS survey, given regional trends toward urbanisation and dietary change.
Tuberculosis remains significant, particularly among people living with HIV. Managing HIV alongside NCDs adds treatment complexity. A 2024 cluster randomised trial (InterCARE) is testing the integration of hypertension and cardiovascular care into existing HIV services at 14 sites across Botswana, enrolling over 4,600 adults.
Digital Health and Data Systems
Botswana was among the first countries in sub-Saharan Africa to deploy a national electronic health records system. The Integrated Patient Management System (IPMS) was rolled out across all public hospitals and is one of the bigger digital health investments Botswana has made over the past decade.
The IPMS was designed to support twelve interoperable modules covering admissions, laboratory, pharmacy, and other hospital functions. Research published in 2023 found that IPMS adoption increased medical practitioner productivity by an average of 65.6 percent. However, implementation has been uneven: in practice, only the admissions, laboratory, and microbiology modules have been fully deployed at most facilities.
Beyond IPMS, Botswana operates several parallel systems:
- District Health Information System (DHIS2) for aggregate reporting
- OpenMRS for clinic-level electronic medical records
- Patient Information Management System (PIMS) as a standalone system at public clinics
The problem is interoperability. These systems were built independently and do not share data easily. That limits the country's ability to generate unified patient-level datasets across facility types and levels of care. Connecting them, whether through national health information exchanges or third-party data platforms, is a priority for the Ministry of Health and Wellness.
Clinical Research Capacity
Botswana's research infrastructure centres on the Botswana Harvard Health Partnership (BHP), a collaboration between the Government of Botswana and Harvard T.H. Chan School of Public Health established in 1996. BHP operates the Botswana Harvard HIV Reference Laboratory, one of the largest HIV/AIDS laboratories in Africa, which serves as the national reference testing facility for all HIV activities.
BHP employs more than 300 scientists, students, and staff members across multiple active clinical research sites throughout the country, and established regulatory, ethics, data management, and laboratory capabilities. Research areas include prevention of mother-to-child transmission, HIV-1C vaccine design, drug resistance monitoring, and adherence studies.
Clinical trials in Botswana are regulated by the Botswana Medicines Regulatory Authority (BoMRA), which approved 10 clinical trial protocols in 2021. The regulatory framework aligns with WHO and ICH guidelines, and Botswana is a member of the African Vaccine Regulatory Forum (AVAREF).
For sponsors considering clinical trials in Africa, Botswana has a well-characterised patient population with long treatment histories, established research ethics infrastructure, and a government that has consistently put money into health research. The small population limits recruitment scale compared to larger markets, but the quality of existing data and institutional partnerships can offset this for certain study designs. Rwanda has followed a similar path, with government investment in health data systems creating parallel opportunities.
Opportunities for Health Data Innovation
Botswana has a 20-year national treatment dataset, established digital health systems, and strong research partnerships. At the same time, it has fragmented information systems, workforce constraints, and a rising NCD burden layered onto an existing HIV treatment infrastructure. Those are exactly the conditions where structured, interoperable health data makes a difference.
The Masa programme dataset alone represents one of the longest continuous ART cohort records in Africa. When linked with NCD screening data, laboratory results, and facility-level outcomes, this information can support treatment protocol optimisation, pharmacovigilance, and market sizing for new therapeutics.
Kapsule's approach to structuring and de-identifying clinical records from African health facilities applies directly to the data challenges Botswana faces. As the country works to connect its IPMS, DHIS2, and OpenMRS systems into a more unified data environment, third-party platforms that can normalise and harmonise records across facility types will become increasingly relevant.
For pharmaceutical companies, CROs, and global health organisations, Botswana is a small but high-quality market: a government that invests in health, a population with well-documented treatment histories, and a regulatory environment that supports clinical research.
Kapsule provides access to structured, de-identified health records from over three million patient encounters across East and West Africa, with standing ethics approvals in Rwanda, Kenya, Uganda, Nigeria, and Ghana. Contact our team to discuss how Southern African health data can support your clinical development and research strategy.
This article is intended for informational purposes only and does not constitute legal, medical, or regulatory advice. Readers should obtain independent professional counsel for their specific circumstances.